Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.29
    -0.94 (-7.69%)

    Market Cap: $689.52M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    4D Molecular Therapeutics Inc (FDMT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect 4D Molecular Therapeutics (FDMT) to earn -$4.16 per share in the fiscal year ending Dec 31, 2026, on revenue of $13.25M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy216.7%
    Buy975.0%
    Hold18.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 51.9%.

    Fiscal year ending Dec 31, 2026
    -$4.16
    EPS consensus, revenue $13.25M
    Fiscal year ending Dec 31, 2027
    -$4.10
    EPS consensus, revenue $20.13M
    Next report
    Mar 16, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.16-$4.30 to -$4.0011$13.25M$6.80M to $22.50M10
    Dec 31, 2027-$4.10-$4.98 to -$3.3810$20.13MN/A8

    Quarterly Estimates

    The EPS consensus falls from -$1.10 for the quarter ending Dec 31, 2026 to -$1.13 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.10-$1.19 to -$1.0013$3.67MN/A11
    Mar 31, 2027-$1.13-$1.19 to -$1.062$2.50MN/A2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202702
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.14.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.16-$4.15-$4.15-$4.15-$4.14N/A
    Fiscal year ending Dec 31, 2027-$4.10-$4.09-$4.09-$4.08-$4.09N/A
    Quarter ending Mar 31, 2027-$1.13-$1.10-$1.10-$1.06-$1.06N/A

    Frequently Asked Questions About FDMT

    What is the FDMT stock forecast?

    Consensus analyst estimates put 4D Molecular Therapeutics's EPS at -$4.16 for the fiscal year ending Dec 31, 2026, on revenue of $13.25M. The consensus rating from 12 analysts is Buy.

    How do analysts rate FDMT stock?

    Of 12 analysts covering 4D Molecular Therapeutics, 2 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from FDMT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.16, with estimates from -$4.30 to -$4.00 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.10, with estimates from -$4.98 to -$3.38 from 10 analysts.

    What revenue do analysts expect from 4D Molecular Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $13.25M, with estimates from $6.80M to $22.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.13M.

    How many analysts cover FDMT?

    12 analysts rate 4D Molecular Therapeutics stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.